Rekombinanter LIV-1 (Ladiratuzumab Biosimilar) Antikörper
Reaktivität: Human
ELISA, BLI, FACS, Func, SPR
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle LIV-1 (Ladiratuzumab Biosimilar) Produkte
- LIV-1 (Ladiratuzumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
- Expressionssystem
- CHO Cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser LIV-1 (Ladiratuzumab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- ELISA, Bio-Layer Interferometry (BLI), Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
- Verwendungszweck
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab)
- Sequenz
- QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
- Produktmerkmale
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
- Reinheit
- >95 %
- Isotyp
- IgG1
-
anti-LIV-1 (Ladiratuzumab Biosimilar) antibody
Research Grade Reaktivität: Human ELISA Wirt: Humanized Monoclonal unconjugated Recombinant Antibody
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Therapeutic Agents by Target and Mechanism: LIV-1 inhibitors
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- +4°C,-80°C
-
- Target
- LIV-1 (Ladiratuzumab Biosimilar)
- Abstract
- LIV-1 (Ladiratuzumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Molekulargewicht
- 145.5 kDa
- UniProt
- Q13433
-
Sie sind hier:
